Tirzide INN Injection Weight-loss

Generic Name: Tirzepatide Injection

English Name: Tirzepatide Injection

Brand Name: Tirzide

Specifications: 2.5 mg/pen/box; 5 mg/pen/box; 7.5 mg/pen/box; 10 mg/pen/box

Manufacturer: Everest Pharmaceuticals Ltd.

Composition

Active Ingredient: Tirzepatide

Excipients: Sucrose, sodium dihydrogen phosphate, sodium hydroxide, water for injection, etc.

Appearance

Clear, colorless to pale yellow liquid; supplied in a pre-filled injection pen.

Pharmacological Action

Tirzepatide is a dual GLP-1R/GIPR agonist that functions by mimicking the effects of incretin hormones:

1. Promotes glucose-dependent insulin secretion and inhibits glucagon secretion;

2. Delays gastric emptying, increases satiety, and reduces food intake;

3. Regulates energy metabolism, significantly reducing body weight, blood glucose, and blood lipids.

Indications

1. Type 2 diabetes in adults: Used as monotherapy or in combination with other glucose-lowering medications to improve glycemic control.

2. Overweight/obesity in adults: Used for weight management in conjunction with diet and exercise.

3. By promoting weight loss, tirzepatide can indirectly alleviate airway compression caused by obesity, thereby relieving snoring symptoms and reducing the loudness of snoring during sleep.

Dosage and Administration

1. Route of Administration: Subcutaneous injection; sites include the abdomen, thigh, or upper arm. Administer once weekly on a chosen day at any time; administration is independent of food intake.

2. Dose Titration

Starting dose: 2.5 mg once weekly for 4 weeks (initial titration dose only; not intended for glycemic control).

Subsequent dose: Increase to 5 mg once weekly after 4 weeks.

For further glycemic control or weight loss: Increase the dose by 2.5 mg every 4 weeks, up to a maximum dose of 15 mg once weekly.

3. Missed Dose: If a dose is missed, it may be administered within 4 days of the scheduled time; if more than 4 days have passed, skip the missed dose and resume the regular schedule. Do not administer a double dose. Contraindications

1. Hypersensitivity to tirzepatide or any excipients.

2. Personal or family history of medullary thyroid carcinoma (MTC).

3. Multiple endocrine neoplasia syndrome type 2 (MEN 2).

Adverse Reactions

Common: Nausea, diarrhea, vomiting, constipation, decreased appetite, dyspepsia, fatigue, dizziness.

Uncommon: Hypoglycemia (risk increased when used with insulin or sulfonylureas), injection site reactions, alopecia, cholelithiasis.

Rare/Serious: Acute pancreatitis, renal impairment, severe allergic reactions, risk of thyroid C-cell tumors.

Precautions

1. Pancreatitis: Discontinue use and seek medical attention immediately if persistent, severe abdominal pain accompanied by vomiting occurs.

2. Hypoglycemia: Dose reduction and blood glucose monitoring are required when used concomitantly with insulin, glimepiride, etc.

3. Gastrointestinal reactions: Rapid dose escalation may exacerbate symptoms; slow titration is recommended.

4. Renal impairment: Severe vomiting and diarrhea may induce renal injury; use with caution in patients with renal insufficiency.

5. Gallbladder disease: Rapid weight loss may increase the risk of cholelithiasis; seek medical evaluation if right upper quadrant abdominal pain occurs.

6. Pregnancy and lactation: Use is not recommended; women of childbearing potential should use contraception during treatment.

7. Driving and operating machinery: Dizziness and hypoglycemia may impair reaction times; exercise caution.

Drug Interactions

1. Concomitant use with insulin or sulfonylureas: Risk of hypoglycemia is significantly increased; dose reduction is required.

2. Delayed gastric emptying: May affect the absorption rate of oral medications (e.g., antibiotics, contraceptives); an interval of at least 1 hour is recommended.

3. Concomitant use with warfarin: May affect INR; enhanced monitoring is required.

Special Populations

Hepatic impairment: No dose adjustment needed for mild to moderate impairment; use with caution in severe impairment.

Renal impairment: Use permitted for mild to moderate impairment; use with caution in end-stage renal disease.

Pediatric use: Safety and efficacy in patients under 18 years of age have not been established; use is not recommended. Elderly patients: No dose adjustment based on age is required; monitor renal function and the risk of hypoglycemia.

Storage

Unopened: Store refrigerated at 2°C–8°C, protect from light, and do not freeze.

Opened/In-use: Store refrigerated at 2°C–8°C or at room temperature (≤30°C); use within 28 days.

Shelf Life

24 months; discard 28 days after first use.

Important Note

This is a prescription medication. Self-purchase, misuse, or use for non-medical weight loss is strictly prohibited. It must not be used for Type 1 diabetes or diabetic ketoacidosis.

In-depth Analysis: Dosage Differences and Efficacy Impact Between the Chinese and Bangladeshi Versions

As a dual-receptor agonist (GLP-1/GIP) used for weight loss and blood glucose control, the clinical efficacy of Tirzepatide is closely linked to the precision of the administered dose. Recently, many users have encountered issues such as "insufficient dosage" or the "inability to extract the full contents" when using different versions of Tirzepatide.

This article uses the common Chinese version (10mg/2.4ml) and the Bangladeshi version (2.5mg/0.5ml) as examples to provide an in-depth analysis of the potential dosage pitfalls.

I. The Core Calculation: Are You Getting the Right Dose?

The standard initial dose of Tirzepatide is typically 2.5mg per week. Let’s calculate the actual drug content for both versions based on their concentrations:

1. Chinese Version (Example: Multi-dose pen/vial)

Specification: 10mg/2.4ml

Concentration: 4.17mg/ml

If 0.5ml is injected: Actual dose administered = 4.17mg/ml × 0.5ml = 2.085mg

Conclusion: If you draw 0.5ml, the actual dose is only 2.08mg, which is significantly lower than the standard 2.5mg.

2. Bangladeshi Version (Example: Single-dose/specific specification)

Specification: 2.5mg/0.5ml

Concentration: 5mg/ml

If 0.5ml is injected: Actual dose administered = 2.5mg. Conclusion: The design of the version for the Bangladesh market aligns better with the clinically standard starting dose, ensuring the full required dosage is administered.

II. The Vanishing 0.4 mL: Why Can the Chinese Version Only Be Injected Four Times?

Regarding the actual use of the Chinese version (10 mg/2.4 mL), many users have reported: "There is 2.4 mL of liquid, and with a 0.5 mL dose per injection, it should theoretically allow for 4.8 injections; why is it impossible to extract the remaining 0.4 mL after the fourth injection?"

This is due to the following two reasons:

1. Dead Space: Whether using an injection pen or a vial, there is physically unextractable "dead space" at the bottom of the container and at the needle connection point.

2. Design Redundancy: When manufacturers design packaging for a total of 10 mg, they typically base it on four standard doses (e.g., 2.5 mg per dose). Because the Chinese version has a lower concentration (4.17 mg/mL), delivering a 2.5 mg dose theoretically requires extracting 0.6 mL; four injections of 0.6 mL would consume exactly 2.4 mL. However, if you only extract 0.5 mL per dose, there is theoretically 0.4 mL left over; yet, due to liquid adhering to the container walls and the limitations of dead space, this residual liquid often cannot be effectively utilized.

Specifications

Product Name: Tirzide INN (Tirzepatide Injection)